Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T09937
(Former ID: TTDI01650)
|
|||||
| Target Name |
Receptor unspecific (Rec)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 4 Target-related Diseases | + | ||||
| 1 | General pain disorder [ICD-11: 8E43] | |||||
| 2 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||||
| 3 | Diabetes mellitus [ICD-11: 5A10] | |||||
| 4 | Oral mucositis [ICD-11: DA01] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 4 Clinical Trial Drugs | + | ||||
| 1 | ATL-104 | Drug Info | Phase 2 | Solid tumour/cancer | [2] | |
| 2 | Prosaptide TX14(A) | Drug Info | Phase 2 | Neuropathic pain | [3], [4] | |
| 3 | BT-063 | Drug Info | Phase 1 | Autoimmune diabetes | [5] | |
| 4 | Lactermin | Drug Info | Phase 1 | Oral mucositis | [6] | |
| Discontinued Drug(s) | [+] 2 Discontinued Drugs | + | ||||
| 1 | PV-707 | Drug Info | Discontinued in Phase 2 | Skin burns | [7] | |
| 2 | YP-004 | Drug Info | Terminated | Solid tumour/cancer | [8] | |
| Mode of Action | [+] 2 Modes of Action | + | ||||
| Modulator | [+] 4 Modulator drugs | + | ||||
| 1 | ATL-104 | Drug Info | [9] | |||
| 2 | Prosaptide TX14(A) | Drug Info | [10] | |||
| 3 | Lactermin | Drug Info | [11] | |||
| 4 | PV-707 | Drug Info | [12] | |||
| Inhibitor | [+] 1 Inhibitor drugs | + | ||||
| 1 | YP-004 | Drug Info | [13] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Biotest. | |||||
| REF 2 | ClinicalTrials.gov (NCT00163280) Safety, Tolerability and Efficacy of ATL-104 in Oral Mucositis. U.S. National Institutes of Health. | |||||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6067). | |||||
| REF 4 | ClinicalTrials.gov (NCT00286377) Safety and Efficacy Study of Prosaptide to Treat Neuropathic Pain in HIV-Positive Patients. U.S. National Institutes of Health. | |||||
| REF 5 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023007) | |||||
| REF 6 | Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr Cancer Drug Targets. 2007 Mar;7(2):157-67. | |||||
| REF 7 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016102) | |||||
| REF 8 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023132) | |||||
| REF 9 | Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial. Bone Marrow Transplant. 2009 Apr;43(7):563-9. | |||||
| REF 10 | Central action of prosaptide TX14(A) against gp120-induced allodynia in rats. European Journal of Pain Volume 12, Issue 1, January 2008, Pages 76-81. | |||||
| REF 11 | Mammalian lactoferrin receptors: structure and function. Cell Mol Life Sci. 2005 Nov;62(22):2560-75. | |||||
| REF 12 | EP patent application no. 1904089, Promotion of epithelial regeneration. | |||||
| REF 13 | CA patent application no. 815512, Method for increasing the efficiency of double-strand break-induced mutagenesis. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.